P529

• CAT Number: I005454
• CAS Number: 914913-88-5
• Molecular Formula: C₂₄H₂₂O₆
• Molecular Weight: 406.43
• Purity: ≥95%
• Target: Akt
• Solubility: DMSO: ≤ 20.5 mg/mL
• Storage: -20°C
• IC50: < 35 uM (GI50, NCI-60 cell lines)
• IUPAC Name: 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one
• InChI: InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3
• InChIKey: YEAHTLOYHVWAKW-UHFFFAOYSA-N
• SMILES: CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O

Palomid 529 (Cat No.:I005454) is a novel non-steroidal small molecule inhibitor. Palomid 529 inhibits mTORC1 and mTORC2 complexes, reduces pAktS473, pGSK3βS9 and pS6 phosphorylation. If you need, please contact us in time, and we will reply to you as soon as possible within 24 hours.

Reference

1:Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. Gravina GL, Marampon F, Sherris D, Vittorini F, Di Cesare E, Tombolini V, Lenzi A, Jannini EA, Festuccia C.Prostate. 2014 Jun;74(8):852-68. doi: 10.1002/pros.22804. Epub 2014 Apr 8. PMID: 24715588 2:Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Dalal M, Jacobs-El N, Nicholson B, Tuo J, Chew E, Chan CC, Nussenblatt R, Ferris F, Meyerle C.Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2705-9. doi: 10.1007/s00417-013-2375-7. Epub 2013 May 21. PMID: 23689994 Free PMC Article3:Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O.Int J Cancer. 2013 Sep 1;133(5):1222-33. doi: 10.1002/ijc.28126. Epub 2013 Apr 1. PMID: 23436212 Free Article4:High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. Lin F, Sherris D, Beijnen JH, Van Tellingen O.J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Dec 15;879(32):3823-31. doi: 10.1016/j.jchromb.2011.10.028. Epub 2011 Oct 29. PMID: 22100549 5:The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Gravina GL, Marampon F, Petini F, Biordi L, Sherris D, Jannini EA, Tombolini V, Festuccia C.Endocr Relat Cancer. 2011 Jul 1;18(4):385-400. doi: 10.1530/ERC-11-0045. Print 2011 Aug. PMID: 21551258 Free Article6:The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Diaz R, Nguewa PA, Diaz-Gonzalez JA, Hamel E, Gonzalez-Moreno O, Catena R, Serrano D, Redrado M, Sherris D, Calvo A.Br J Cancer. 2009 Mar 24;100(6):932-40. doi: 10.1038/sj.bjc.6604938. Epub 2009 Feb 24. PMID: 19240717 Free PMC Article7:Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE.Cancer Res. 2008 Nov 15;68(22):9551-7. doi: 10.1158/0008-5472.CAN-08-2058. PMID: 19010932 Free PMC Article